EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

43
EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012

Transcript of EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Page 1: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

EPIDEMIOLOGY OF HEME MALIGNANCIES

Julie Kasperzyk, ScD

January 11, 2012

Page 2: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Background

Page 3: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Roman & Smith Histopathology 2011, 58, 4–14.

Global Cancer Frequency

Page 4: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Definition: Hematological malignancies Group of cancers that affect the blood,

lymph nodes, and bone marrow Account for ~9% of new cancer

diagnoses in the US 3 major groups

Leukemia: starts in bone marrow and spreads to blood/periphery

Lymphoma: occurs in lymphoid tissue Plasma cell neoplasms (e.g. multiple

myeloma)

Page 5: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Overview of blood cells

Page 6: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

All heme malignancies

(100%)Leukemi

a(~40%)

Acute Lymphocytic (ALL): most common childhood leukemia

Chronic Lymphocytic (CLL): most common leukemia in elderly

Acute Myeloid (AML)

Chronic Myeloid (CML): more common in adults, rare in children

Other leukemias

Lymphoma

(~50%)Non-Hodgkin lymphoma (NHL): many histological subtypes, more common than HL

Hodgkin lymphoma (HL): morphologically distinct Reed-Sternberg cells

Plasma Cell

Neoplasm(~10%)

Multiple myeloma (MM)

Other

Page 7: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Global lymphoma incidence

Page 8: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Multiple myeloma

Hodgkin lymphoma

Non-Hodgkin lymphoma

Leukemia

0 2 4 6 8 10 12 14

Northern AmericaLatin AmericaAsiaAfrica

Per 100,000

Age-standardized rates of heme cancers in selected regions

GLOBOCAN 2008, IARC

Page 9: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Surveillance, Epidemiology and End Results (SEER) Program. A source for US cancer statistics.

Heme cancer incidence rates in the US from 1975-2007

Page 10: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Heme cancer mortality rates in the US from 1975-2007

Page 11: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

www.lls.org

Page 12: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Leukemia

Page 13: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Acute vs. chronic

Acute Elevated immature blood cells in the marrow and

blood Rapid progression and accumulation of malignant

cells Requires immediate treatment ALL is most common form of leukemia in children

Chronic Elevated mature (or relatively mature) blood cells Takes months to years to progress Sometimes treated conservatively (esp. low-grade) Mostly occurs at older ages

Page 14: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Number of new cases & deaths in US, 2010

ALL

AML

CLLCM

L

Other

/unc

lass

ified

02000400060008000

10000120001400016000

New CasesDeaths

Page 15: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates of Acute Leukemia (ALL & AML) by age and sex, US

ALL AML

Page 16: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

ALL

Can involve B (~85%) or T (~15%) lymphocytes, rarely natural killer cells

Risk factors largely unknown Ionizing radiation Higher rates found in more developed

countries and families with higher SES 5-year survival

66% for all ages 91% for children under 5 yrs

www.lls.org

Page 17: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

AML

Involves myeloid progenitor cells Potential risk factors:

Chronic benzene exposure (found in cigarette smoke)

Certain genetic disorders Down syndrome increased risk of AML

Past chemo or radiation therapy History of other blood cancers or disorders

5-year survival 24% for all ages 61% for children under 15 yrs

www.lls.org

Page 18: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates of Chronic Leukemia (CLL & CML) by age and sex, US

CLL CML

Page 19: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

CLL

Most common type of leukemia in adults Begins in the bone marrow and can progress

either slowly or quickly depending on subtype 95% are B lymphocyte origin, with remaining

5% either T cell or natural killer cell origin Risk factors

Family history (1st degree relatives of CLL cases are 3-4x more likely to develop CLL than people without family Hx)

Vietnam veterans (agent orange exposure) 5-year survival: 80% for all ages

Page 20: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

CML

Involves proliferation of mature and immature myeloid cells, accumulate in bone marrow and blood

Potential risk factors Ionizing radiation Radiation therapy from treatment of other

cancers 5-year survival: 55% for all ages

Page 21: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

CML and the Philadelphia chromosome

Translocation between BCR and c-ABL

BCR-ABL acts as a tyrosine kinase, and constitutive expression increases rate of mitosis and decreases apoptosis

Treated with tyrosine kinase inhibitors (eg Gleevec) which has dramatically improved survival

http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CML.html

Page 22: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Leukemia rates by race/ethnicity, US

Source: SEER

Page 23: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Atomic bomb survivors

J Radiat Res (Tokyo). 1991 Dec;32 Suppl 2:54-63.

Page 24: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Treatments for leukemia

Depends on subtype and risk factors Multi-drug chemotherapy regimen Less common: radiation therapy or bone

marrow transplant Consequence if untreated: disruption of

normal blood production Anemia: caused by low levels of RBC production Neutropenia: more susceptible to infections due

to low numbers of neutrophils (a type of WBC) Bleeding/bruising: caused by low platelet levels

Page 25: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Lymphoma

Page 26: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Non-Hodgkin (NHL) & Hodgkin (HL) Affect the lymphatic system NHL: Mostly (~85%) B-cell origin, and

remaining 15% T-cell or natural killer cell origin

HL: B-cell origin Major risk factors

Male gender Caucasian race Immunodeficiency syndromes (acquired

and inherited)

Page 27: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Lymphoma subtype frequencies

Roman & Smith Histopathology 2011, 58, 4–14.

Hodgkin lymphoma subtypes

Source: Haematological Malignancy Research Network, 2004-2009

Page 28: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

New Cases Deaths0

10000

20000

30000

40000

50000

60000

70000

NHLHL

Number of new cases & deaths in US, 2010

Page 29: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates of NHL & HL by age, US

Page 30: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates of NHL & HL by age and sex, US

Page 31: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates over time of NHL & HL by race/ethnicity, US

NHL HL Source: SEER

Page 32: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Epstein-Barr Virus (EBV)

Herpesvirus family Infects nasopharyngeal epithelial cells

and B lymphocytes Promotes proliferation of infected cells

Ubiquitous in human populations worldwide Childhood infections are generally mild Adolescent/adult infection can lead to

mononucleosis

Page 33: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

EBV & Burkitt lymphoma

Rare, aggressive NHL with B-cell origin Endemic in regions of Africa where Epstein-Barr

virus (EBV) and malaria are common Malaria causes T cell immunodeficiency

Occurs typically in young children, beginning in the lymph nodes in the neck

Nearly 100% of tumors from African Burkitt’s lymphoma carry the EBV genome and express EBV-encoded antigens

Other types (weakly linked to EBV): sporadic (non-African) immunodeficiency-associated

Page 34: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

EBV & HL

~1/3 of tumors positive for EBV in developed countries

2- to 3- fold increased HL risk with history of infectious mononucleosis

Hygiene hypothesis Lower risk with daycare, higher birth order,

larger sibship size

Mueller & Grufferman. Hodgkin Lymphoma in Cancer Epidemiology and Prevention. 3rd edition.

Page 35: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

HTLV-1 & adult T-cell leukemia/lymphoma (ATLL)

Human T-lymphotropic virus type 1 (HTLV-1) Endemic to Japan, Caribbean, & parts of

Central Africa Immortalizes infected T-cells (similar to

HIV) HTLV-1 is a necessary but not sufficient

cause of ATLL ~3% of infected individuals develop ATLL

Page 36: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

HIV & lymphoma

HIV weakens the immune system

More susceptible to other infectious agents (e.g. EBV) that increase lymphoma risk

Introduction of antiretroviral therapy has reduced incidence of NHL among HIV-infected individuals

Engels et al. Int J Cancer. 2008;123:187-94.

Page 37: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Treatment for lymphoma

Primarily chemotherapy and radiation therapy In some cases: bone marrow transplant or

immunotherapy 5-year survival rate in US

NHL 1960-1963 (Caucasians only): 31% 1999-2006 (all races): 69%

HL 1960-1963 (Caucasians only): 40% 1999-2006 (all races): 88% Persons <20 yrs old: 96%

Page 38: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Multiple Myeloma

Page 39: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

MM

Cancer of plasma cells (mature B lymphocytes), amass primarily in the bone marrow

Risk factors Male gender African American race/ethnicity History of MGUS (monoclonal gammopathy of

unknown significance) Environmental exposures (Agent Orange,

smoking, radiation, pesticides) Obesity

www.lls.org

Page 40: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates of MM by age and sex, US

Page 41: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Rates over time of MM by race/ethnicity, US

Source: SEER

Page 42: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Obesity & MM

RR for obesity vs. normal weight

Overall: RR=1.21

Wallin & Larssen. European Journal Of Cancer 2011;47:1606-15.

Page 43: EPIDEMIOLOGY OF HEME MALIGNANCIES Julie Kasperzyk, ScD January 11, 2012.

Treatment for multiple myeloma Drug therapy (including chemotherapy),

stem cell transplantation, radiation therapy

5-year survival 1960-1963 (Caucasians only): 12% 1999-2006 (all races): 39%